Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.

de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS.

Sci Transl Med. 2018 May 9;10(440). pii: eaar5894. doi: 10.1126/scitranslmed.aar5894.

PMID:
29743350
2.

Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.

King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF 3rd.

Urol Oncol. 2018 Apr;36(4):157.e15-157.e20. doi: 10.1016/j.urolonc.2017.11.022. Epub 2017 Dec 21.

PMID:
29276060
3.

Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.

Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF 3rd.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):53-58. doi: 10.1016/j.ijrobp.2017.08.046. Epub 2017 Sep 9.

PMID:
29254781
4.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
5.

American College of Radiology-American Brachytherapy Society practice parameter for electronically generated low-energy radiation sources.

Devlin PM, Gaspar LE, Buzurovic I, Demanes DJ, Kasper ME, Nag S, Ouhib Z, Petit JH, Rosenthal SA, Small W Jr, Wallner PE, Hartford AC.

Brachytherapy. 2017 Nov - Dec;16(6):1083-1090. doi: 10.1016/j.brachy.2017.08.002. Epub 2017 Oct 5.

PMID:
28988661
6.

Custom-made micro applicators for high-dose-rate brachytherapy treatment of chronic psoriasis.

Buzurovic IM, O'Farrell DA, Bhagwat MS, Hansen JL, Harris TC, Friesen S, Cormack RA, Devlin PM.

J Contemp Brachytherapy. 2017 Jun;9(3):263-269. doi: 10.5114/jcb.2017.68304. Epub 2017 Jun 13.

7.

Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis.

Mangione FM, Jatene T, Badr Eslam R, Bergmark BA, Gallagher JR, Shah PB, Mauri L, Leopold JA, Sobieszczyk PS, Faxon DP, Croce KJ, Bhatt DL, Devlin PM.

Am J Cardiol. 2017 Aug 1;120(3):369-373. doi: 10.1016/j.amjcard.2017.04.036. Epub 2017 May 10.

PMID:
28583681
8.

The value of systematic contouring of the bowel for treatment plan optimization in image-guided cervical cancer high-dose-rate brachytherapy.

Damato AL, Buzurovic I, Bhagwat MS, Cormack RA, Devlin PM, Friesen S, Hansen J, Lee LJ, Manuel MM, Cho LP, O'Farrell D, Viswanathan AN.

Brachytherapy. 2017 May - Jun;16(3):579-585. doi: 10.1016/j.brachy.2017.01.008. Epub 2017 Feb 27.

PMID:
28256433
9.

Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau.

Pinard J, Vleugels RA, Kurtzman DJ, Devlin PM, Patel M.

JAMA Dermatol. 2017 Apr 1;153(4):331-332. doi: 10.1001/jamadermatol.2016.5142. No abstract available.

PMID:
28122079
10.

High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.

Ho KJ, Devlin PM, Madenci AL, Semel ME, Gravereaux EC, Nguyen LL, Belkin M, Menard MT.

J Vasc Surg. 2017 Mar;65(3):734-743. doi: 10.1016/j.jvs.2016.10.002. Epub 2016 Dec 13.

PMID:
27986482
11.

Skin surface brachytherapy: A survey of contemporary practice patterns.

Likhacheva AO, Devlin PM, Shirvani SM, Barker CA, Beron P, Bhatnagar A, Doggett SW, Hochman L, Hsu C, Kasper M, Keisch M, Mutyala S, Prestidge B, Rodriguez Villalba S, Shukla V, Sundararaman S, Kamrava M.

Brachytherapy. 2017 Jan - Feb;16(1):223-229. doi: 10.1016/j.brachy.2016.10.006. Epub 2016 Nov 28.

12.

Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience.

Cho LP, Manuel M, Catalano P, Lee L, Damato AL, Cormack RA, Buzurovic I, Bhagwat M, O'Farrell D, Devlin PM, Viswanathan AN.

Gynecol Oncol. 2016 Dec;143(3):545-551. doi: 10.1016/j.ygyno.2016.09.017. Epub 2016 Oct 6.

PMID:
27720445
13.

Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer.

Buzurovic IM, Hansen JL, Bhagwat MS, O'Farrell DA, Friesen S, Harris TC, Damato AL, Cormack RA, Martin NE, Devlin PM.

J Contemp Brachytherapy. 2016 Aug;8(4):319-25. doi: 10.5114/jcb.2016.61933. Epub 2016 Aug 23.

14.

Successful use of brachytherapy for a severe hidradenitis suppurativa variant.

Paul S, Bach D, LeBoeuf NR, Devlin PM, Lipworth AD.

Dermatol Ther. 2016 Nov;29(6):455-458. doi: 10.1111/dth.12393. Epub 2016 Jul 18.

PMID:
27425163
15.

Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis.

Timerman D, Devlin PM, Nambudiri VE, Wright NA, Vleugels RA, Clark RA, Kupper TS, Merola JF, Patel M.

Clin Exp Dermatol. 2016 Jul;41(5):498-501. doi: 10.1111/ced.12803. Epub 2016 Feb 5.

16.

Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy.

Goddard AL, Vleugels RA, LeBoeuf NR, O'Farrell DA, Cormack RA, Hansen JL, Kupper TS, Devlin PM.

JAMA Dermatol. 2015 Dec 1;151(12):1354-1357. doi: 10.1001/jamadermatol.2015.3028.

PMID:
26397774
17.

Brachytherapy in the treatment of recurrent aggressive falcine meningiomas.

Abou Al-Shaar H, Almefty KK, Abolfotoh M, Arvold ND, Devlin PM, Reardon DA, Loeffler JS, Al-Mefty O.

J Neurooncol. 2015 Sep;124(3):515-22. doi: 10.1007/s11060-015-1873-3. Epub 2015 Aug 8.

PMID:
26253325
18.

Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer.

Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF 3rd, Nguyen PL.

Brachytherapy. 2015 Jul-Aug;14(4):511-6. doi: 10.1016/j.brachy.2015.03.004. Epub 2015 Apr 14.

PMID:
25887342
19.

Independent brachytherapy plan verification software: improving efficacy and efficiency.

Damato AL, Devlin PM, Bhagwat MS, Buzurovic I, Friesen S, Hansen JL, Lee LJ, Molodowitch C, Nguyen PL, O'Farrell DA, Viswanathan AN, Williams CL, Killoran JH, Cormack RA.

Radiother Oncol. 2014 Dec;113(3):420-4. doi: 10.1016/j.radonc.2014.09.015. Epub 2014 Oct 23.

PMID:
25458129
20.

High-dose-rate Interstitial Brachytherapy Boost with a Pedicled Latissimus Dorsi Myocutaneous Flap for Myxofibrosarcoma of the Arm.

Lane JD, Pomahac B, Raut CP, Baldini EH, Devlin PM.

Plast Reconstr Surg Glob Open. 2014 Nov 7;2(10):e229. doi: 10.1097/GOX.0000000000000188. eCollection 2014 Oct.

21.

Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas.

Fairweather M, Wang J, Devlin PM, Hansen J, Baldini EH, Ready JE, Sugarbaker DJ, Bertagnolli MM, Raut CP.

Ann Surg Oncol. 2015 May;22(5):1455-63. doi: 10.1245/s10434-014-4171-y. Epub 2014 Oct 24.

PMID:
25341749
22.

Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series.

Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF 3rd, Niedermayr TR, Suh WW, Devlin PM, Tempany CM, Sugar EH, O'Farrell DA, Steele G, O'Leary M, Buzurovic I, Damato AL, Cormack RA, Fedorov AY, Nguyen PL.

Radiat Oncol. 2014 Sep 9;9:200. doi: 10.1186/1748-717X-9-200.

23.

Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.

Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL.

Brachytherapy. 2014 Sep-Oct;13(5):442-9. doi: 10.1016/j.brachy.2014.05.001. Epub 2014 May 28.

PMID:
24880584
24.

Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planning.

Niedermayr TR, Nguyen PL, Murciano-Goroff YR, Kovtun KA, Neubauer Sugar E, Cail DW, O'Farrell DA, Hansen JL, Cormack RA, Buzurovic I, Wolfsberger LT, O'Leary MP, Steele GS, Devlin PM, Orio PF 3rd.

Brachytherapy. 2014 Jul-Aug;13(4):375-9. doi: 10.1016/j.brachy.2014.01.009. Epub 2014 Mar 5.

PMID:
24613569
25.

PSA screening: the case in favor.

Nguyen PL, Hyatt AS, Devlin PM.

Oncology (Williston Park). 2013 Oct;27(10):980, 982. No abstract available.

26.

Equivalent uniform dose for accelerated partial breast irradiation using the MammoSite applicator.

Stewart AJ, Hepel JT, O'Farrell DA, Devlin PM, Price LL, Dale RG, Wazer DE.

Radiother Oncol. 2013 Aug;108(2):232-5. doi: 10.1016/j.radonc.2013.06.030. Epub 2013 Jul 25.

PMID:
23891101
27.

Palliative treatment for in-transit cutaneous metastases of Merkel cell carcinoma using surface-mold computer-optimized high-dose-rate brachytherapy.

Garibyan L, Cotter SE, Hansen JL, Noell C, Dorosario A, O'Farrell DA, Devlin PM, Wang LC.

Cancer J. 2013 Jul-Aug;19(4):283-7. doi: 10.1097/PPO.0b013e31829e3566.

28.

Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma.

DeSimone JA, Guenova E, Carter JB, Chaney KS, Aldridge JR, Noell CM, Dorosario AA, Hansen JL, Kupper TS, Devlin PM.

J Am Acad Dermatol. 2013 Jul;69(1):61-5. doi: 10.1016/j.jaad.2012.12.975. Epub 2013 Feb 26.

PMID:
23453243
29.

American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy.

Holloway CL, Delaney TF, Alektiar KM, Devlin PM, O'Farrell DA, Demanes DJ.

Brachytherapy. 2013 May-Jun;12(3):179-90. doi: 10.1016/j.brachy.2012.12.002. Epub 2013 Feb 20. Review.

30.

Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation.

McBride SM, Raut CP, Lapidus M, Devlin PM, Marcus KJ, Bertagnolli M, George S, Baldini EH.

Ann Surg Oncol. 2013 Jul;20(7):2140-7. doi: 10.1245/s10434-013-2868-y. Epub 2013 Feb 8.

PMID:
23392853
31.

Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface.

Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP.

Ann Surg Oncol. 2013 May;20(5):1494-9. doi: 10.1245/s10434-012-2797-1. Epub 2012 Dec 15.

PMID:
23242820
32.

Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer.

Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):355-62. doi: 10.1016/j.ijrobp.2012.08.021. Epub 2012 Oct 3.

33.

Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy.

Zelefsky MJ, Cohen GN, Bosch WR, Morikawa L, Khalid N, Crozier CL, Lee WR, Zietman A, Owen J, Wilson JF, Devlin PM.

Brachytherapy. 2013 Jan-Feb;12(1):19-24. doi: 10.1016/j.brachy.2012.04.001. Epub 2012 Jul 21.

34.

High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature.

Nguyen PL, Devlin PM, Beard CJ, Orio PF 3rd, O'Leary MP, Wolfsberger LD, O'Farrell DA, Sweeney CM, Hadaschik BA, Hohenfellner M, Hatiboglu G.

Brachytherapy. 2013 Jan-Feb;12(1):77-83. doi: 10.1016/j.brachy.2012.03.005. Epub 2012 Apr 28. Review.

35.

Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity.

Cotter SE, Dunn GP, Collins KM, Sahni D, Zukotynski KA, Hansen JL, O'Farrell DA, Ng AK, Devlin PM, Wang LC.

Arch Dermatol. 2011 Jul;147(7):870-2. doi: 10.1001/archdermatol.2011.176. No abstract available.

PMID:
21768497
36.

Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.

Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e813-8. doi: 10.1016/j.ijrobp.2010.12.005. Epub 2011 Feb 6.

PMID:
21300455
37.

Treatment of cutaneous metastases of Merkel cell carcinoma with surface-mold computer-optimized high-dose-rate brachytherapy.

Cotter SE, Devlin PM, Sahni D, Hansen JL, O'Farrell DA, Ng AK, Wang LC.

J Clin Oncol. 2010 Sep 20;28(27):e464-6. doi: 10.1200/JCO.2010.29.0635. Epub 2010 Aug 2. No abstract available.

PMID:
20679604
38.

Mammographic appearance following accelerated partial breast irradiation by using MammoSite brachytherapy.

Ahmed HM, Dipiro PJ, Devlin PM, Nguyen ML, Bellon JR.

Radiology. 2010 May;255(2):362-8. doi: 10.1148/radiol.10091625. Epub 2010 Mar 23.

PMID:
20332376
39.

Partial breast irradiation: a review of techniques and indications.

Stewart AJ, Khan AJ, Devlin PM.

Br J Radiol. 2010 May;83(989):369-78. doi: 10.1259/bjr/11505970. Epub 2010 Mar 11. Review.

40.

Rebuttal to Drs. Davidson, Hendry, and West: once burned, twice shy?

Mutyala S, Devlin PM, Stewart AJ.

Brachytherapy. 2009 Jul-Sep;8(3):277. doi: 10.1016/j.brachy.2009.06.002. No abstract available.

PMID:
19643376
41.

Counterpoint: the dose rate argument--Does size matter after all?

Stewart AJ, Devlin PM, Mutyala S.

Brachytherapy. 2009 Jul-Sep;8(3):273-5. doi: 10.1016/j.brachy.2009.06.003. No abstract available.

PMID:
19643374
42.

Permanent iodine-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies.

Mutyala S, Stewart A, Khan AJ, Cormack RA, O'Farrell D, Sugarbaker D, Devlin PM.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1114-20. doi: 10.1016/j.ijrobp.2009.02.067. Epub 2009 Jun 18.

PMID:
19540065
43.

Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report.

Siddiqi NH, Devlin PM.

J Vasc Interv Radiol. 2009 May;20(5):664-9. doi: 10.1016/j.jvir.2009.01.023. Epub 2009 Mar 27.

PMID:
19328722
44.

Intraoperative seed placement for thoracic malignancy-A review of technique, indications, and published literature.

Stewart AJ, Mutyala S, Holloway CL, Colson YL, Devlin PM.

Brachytherapy. 2009 Jan-Mar;8(1):63-9. doi: 10.1016/j.brachy.2008.09.002. Epub 2008 Dec 3. Review.

PMID:
19056322
45.
46.

Intersociety Radiation Oncology Summit-SCOPE II.

Tripuraneni P, Watson RL, Ang KK, Harrison L, Eifel P, Zietman A, Haffty B, Thevenot LI, Willett CG, Schomberg PJ, Pickles T, Halberg FE, Devlin PM.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):323-6. doi: 10.1016/j.ijrobp.2008.06.1904. No abstract available.

PMID:
18793951
47.

Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.

Siddiqi NH, Khan AJ, Devlin PM.

Cardiovasc Intervent Radiol. 2009 Jan;32(1):47-51. doi: 10.1007/s00270-008-9428-z. Epub 2008 Sep 9.

PMID:
18779994
48.

Brachytherapy partial breast irradiation: analyzing effect of source configurations on dose metrics relevant to toxicity.

Cormack RA, Devlin PM.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):940-4. doi: 10.1016/j.ijrobp.2008.03.002.

PMID:
18514786
49.

Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate.

Albert M, Song JS, Schultz D, Cormack RA, Tempany CM, Haker S, Devlin PM, Beard C, Hurwitz MD, Suh WW, Jolesz F, D'Amico AV.

Urol Oncol. 2008 Mar-Apr;26(2):147-52. doi: 10.1016/j.urolonc.2007.03.026. Epub 2007 Oct 29. Review.

PMID:
18312933
50.

Permanent planar iodine-125 implants: the dosimetric effect of geometric parameters for idealized source configurations.

Cormack RA, Holloway CL, O'Farrell D, Devlin PM.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1310-5.

PMID:
17967321

Supplemental Content

Loading ...
Support Center